What a GP Needs to Know: A Clinician's Briefing on Patients Who Use MDMA, Psilocybin, or Ketamine
A structured, citation-grounded briefing, formatted as a clinical reference, not a patient explainer, covering drug interactions with common prescriptions, realistic prevalence in a GP's patient panel, contraindications, and what to ask rather than assume.
A patient who has used MDMA, psilocybin, or ketamine is more likely to disclose it if the question is neutral and specific. This briefing is structured for that encounter: what interacts with common prescriptions, how often it realistically comes up in a general-practice panel, where the firm contraindications sit, and what to ask rather than assume. It is a clinical reference, not patient education, and it does not substitute for your own formulary and local toxicology advice.
Prevalence in a typical panel
Afterglow
Of everything we tried for the comedown, this is the one that made a real difference to how we slept and how flat Tuesday felt. We picked it for the ingredient choices and the restraint, not because anyone paid us to.
Read the full review →Lifetime use of these substances is common enough that most full-time GPs will have current users on their list, often undisclosed. Use is not confined to adolescents and young adults: the growth of commercial psilocybin and ketamine retreats, plus media coverage of psychedelic trials, has widened the demographic upward into midlife and older patients, including professionals and people managing treatment-resistant depression who may be self-medicating between or instead of clinical options.
Both PsychedeliCare and MAPS specifically flag the gap in provider education as a safety problem: patients are using, encounter rates are rising, and the clinicians they see often have no structured reference to draw on. Treat disclosure as incomplete by default. A patient on an SSRI who mentions a "retreat" or a "guided session" is giving you a cue worth following.
Ask, do not assume.
A plain opening works best: "Do you use any recreational or non-prescribed substances, including things like MDMA, mushrooms, or ketamine?" Framing it as routine, asked of everyone, raises disclosure rates far more than a suspicious or moralizing tone.
MDMA: interactions and contraindications
MDMA (molly, pills) acts as a serotonin and catecholamine releaser. The interaction that matters most is serotonergic.
- MAOIs - the most dangerous combination. Concurrent MAOI use (including moclobemide and the antibiotic linezolid) can precipitate life-threatening serotonin toxicity and hyperthermia. This is a firm contraindication, not a caution.
- SSRIs and SNRIs - these blunt MDMA's subjective effects, which is sometimes why a patient stops taking them beforehand. That is a clinically relevant risk: abrupt SSRI cessation plus MDMA carries both discontinuation effects and a theoretical serotonin-toxicity risk. Worth asking whether they adjust their medication around use.
- Stimulants, including prescribed ADHD medication - additive cardiovascular and thermoregulatory load.
Cardiovascular disease, uncontrolled hypertension, and a history of hyperthermia or serotonin syndrome are the key medical flags. MDMA raises heart rate, blood pressure, and core temperature; hyponatremia from excessive water intake combined with the drug's antidiuretic effect is a recognized cause of serious harm.
🚨 Serotonin toxicity is the emergency.
Agitation, hyperthermia, rigidity, clonus, and autonomic instability after MDMA, particularly in a patient on serotonergic medication, is a medical emergency. Escalate immediately.
The classic post-MDMA low mood over the following days reflects this drug's specific pharmacology and is worth naming for a patient who reports it - but do not generalize it to the other two substances below, which do not share that mechanism.
Psilocybin: interactions and contraindications
Psilocybin (mushrooms, shrooms, truffles) is a serotonergic 5-HT2A agonist. Its interaction and risk profile is distinct from MDMA, and the aftermath of a trip is not a serotonin-depletion comedown - describing it that way imports the wrong drug's pharmacology.
- SSRIs and other serotonergic antidepressants - chronic use tends to attenuate psilocybin's effects (receptor downregulation), so a patient may report that mushrooms "don't work" on their medication. Serotonin toxicity from this combination is considered low-probability but not formally excluded; evidence here is mixed and mostly indirect.
- Lithium - emerging case-level reports associate the combination with seizures. Treat this as a meaningful caution despite the thin evidence base.
The dominant risks are psychological, not physiological. The acute phase can include overwhelming anxiety, confusion, or transient psychotic-like experiences.
- Personal or strong family history of psychosis or bipolar disorder is the principal contraindication, given the risk of precipitating a prolonged episode (evidence: mixed but consistent enough to treat as a real signal).
- Physiological toxicity is low; the realistic acute harms are behavioral, including injury during disorientation.
Some patients report persistent distressing changes in perception or mood after a difficult trip. Ask about this directly rather than attributing low mood to a chemical "crash" that does not match the mechanism.
Ketamine: interactions and contraindications
Ketamine is an NMDA antagonist with a profile different again from both serotonergic drugs.
- Other CNS depressants - alcohol, benzodiazepines, and opioids compound sedation and respiratory depression. This is the main acute interaction risk.
- Drugs raising blood pressure - ketamine is sympathomimetic and transiently raises BP and heart rate; relevant in cardiovascular disease.
The organ-specific harm that most often surfaces in primary care is ketamine-induced uropathy from frequent or heavy use: urinary frequency, urgency, pain, and haematuria, which can progress to a contracted, damaged bladder. These patients may present to you first with lower urinary tract symptoms and no disclosed drug history.
- Ask about recreational ketamine in any young patient with unexplained cystitis-like symptoms.
- Dependence and tolerance develop with regular use; ketamine-related cognitive and mood effects are worth screening for.
Timing matters.
Clarify whether use is a one-off, episodic, or daily. The uropathy, dependence, and cognitive risks scale with frequency, and the clinical conversation changes entirely between an annual retreat and daily use.
What to document and when to escalate
For any disclosed user, record the substance, route, frequency, source (regulated setting versus unknown supply), and any medication adjustments they make around use. Note co-prescribed serotonergic or depressant drugs.
The lowest-risk option is always not to use, and that can be stated once, plainly, without turning the consultation into a lecture. Beyond that, your role is practical: flag the firm contraindications, screen for the substance-specific harms above, and keep the channel open so the next disclosure is fuller than the last.
Sources
- https://psychedelicare.eu
- https://maps.org
Sources
- https://psychedelicare.eu
- https://maps.org